Get started
Author

Rajwinder Lehal

Observed names: Lehal, Rajwinder, R Lehal, R. Lehal, Raj Lehal, Rajwinder S. Lehal
Observed institutions: University Health Network, University of Toronto, Allgemeine Gewerbeschule Basel, ISREC Foundation, Campbell Family Institute for Breast Cancer Research, École Polytechnique Fédérale de Lausanne, Louisiana State University Health Sciences Center New Orleans
ORCID: 0000-0002-9508-7553
Observed ORCID: 0000-0002-9508-7553
OpenAlex ID: A5036605384
Stem cells living with a Notch
2013 · Ute Koch, Rajwinder Lehal, et al. · Development · 295
PDF
Identification of Tumorsphere- and Tumor-Initiating Cells in HER2/Neu-Induced Mammary Tumors
2007 · Jeff C. Liu, Tao Deng, et al. · Cancer Research · 163
PDF
Pharmacological disruption of the Notch transcription factor complex
2020 · Rajwinder Lehal, Jelena Zaric, et al. · Proceedings of the National Academy of Sciences · 113
Alzheimer’s disease mutations in APP but not γ-secretase modulators affect epsilon-cleavage-dependent AICD production
2013 · Mitko Dimitrov, Jean-René Alattia, et al. · Nature Communications · 93
PDF
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors
2023 · Glenn J. Hanna, Anastasios Stathis, et al. · Cancer Research Communications · 49
PDF
Very High Throughput Electrical Cell Lysis and Extraction of Intracellular Compounds Using 3D Carbon Electrodes in Lab-on-a-Chip Devices
2012 · Guillaume Mernier, Rodrigo Martinez-Duarte, et al. · Micromachines · 37
PDF
Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
2021 · Hayley M. Sabol, Adam J. Ferrari, et al. · Cancer Research · 36
PDF
Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers.
2021 · Elena Lopez Miranda, Anastasios Stathis, et al. · Journal of Clinical Oncology · 24
Generation and characterization of a Notch1 signaling‐specific reporter mouse line
2012 · Emma Smith, Stéphanie Claudinot, et al. · genesis · 20
The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer
2023 · Michele Vigolo, Charlotte Urech, et al. · Cancers · 19
PDF
CB‐103: A novel CSL‐NICD inhibitor for the treatment of NOTCH‐driven T‐cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T‐ALL
2022 · Michael Medinger, Till Junker, et al. · eJHaem · 19
Notch Inhibition in Cancer: Challenges and Opportunities
2020 · Doriano Fabbro, Michael Bauer, et al. · CHIMIA International Journal for Chemistry · 18
PDF
First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.
2018 · Jose Manuel Perez Garcia, Javier Cortés, et al. · Journal of Clinical Oncology · 13
In vitro anti‐lymphoma activity of the first‐in‐class pan‐NOTCH transcription inhibitor CB ‐103
2022 · Filippo Spriano, Chiara Tarantelli, et al. · British Journal of Haematology · 5
PDF
Pharmacological activity of CB-103: An oral pan-NOTCH inhibitor with a novel mode of action
2017 · D. Weber, R. Lehal, et al. · Annals of Oncology · 5
Pharmacological Activity of Cb‐103 in Haematological Malignancies – an Oral Pan‐notch Inhibitor With a Novel Mode of Action
2017 · D. Weber, R. Lehal, et al. · Hematological Oncology · 5
PDF
Pharmacological activity of CB-103: An oral pan-NOTCH inhibitor targeting the NOTCH transcription complex
2018 · D. Weber, R. Lehal, et al. · Annals of Oncology · 4
Abstract B061: Targeting lymphomas with the novel first-in-class pan-NOTCH transcription inhibitor CB-103
2018 · Filippo Spriano, Chiara Tarantelli, et al. · Molecular Cancer Therapeutics · 4
Gene expression patterns in adenoid cystic carcinoma with and without diffuse NOTCH1 intracellular domain (NICD1) immunohistochemistry staining
2023 · Karan Patel, Massimiliano Manzo, et al. · Oral Oncology · 2
Notch Signaling In Normal And Malignant T-Cells
2012 · Freddy Radtke, Ute Koch, et al. · Infoscience (Ecole Polytechnique Fédérale de Lausanne) · 2
562P Target engagement and clinical safety of CB-103, a first-in-class small molecule inhibitor of the NOTCH transcription complex
2020 · A.B. Azaro Pedrazzoli, J.M. Perez Garcia, et al. · Annals of Oncology · 1
Abstract 5799: Characterization and profiling of CB-103, a novel small-molecule protein-protein interaction inhibitor targeting the NOTCH transcription complex
2018 · Rajwinder Lehal, Charlotte Urech, et al. · Cancer Research · 1
Pharmacological Activity Of Cb-103-An Oral Pan-Notch Inhibitor With A Novel Mode Of Action
2017 · Rajwinder Lehal, Donald A. Weber, et al. · Infoscience (Ecole Polytechnique Fédérale de Lausanne) · 1
FIGURE 1 from A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors
2023 · Glenn J. Hanna, Anastasios Stathis, et al.
Data from A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors
2023 · Glenn J. Hanna, Anastasios Stathis, et al.
Works count: 53
Citation count: 929
H-index: 13
I10-index: 13
Year
Topic
Type